Signal from the log
Kasvu Therapeutics
30 M€ · Series A · Finland · Biotech
Kasvu Therapeutics développe des petites molécules qui amplifient le signal naturel du BDNF dans le cerveau, par le récepteur TrkB, au lieu de passer par le récepteur des psychédéliques. Son candidat KTX-0141 vise la dépression majeure, avec une entrée en clinique annoncée pour le second semestre 2027.
Verified
Announced on , logged by the watch of 24 September 2026.
- Operation
- Funding round
- Announced amount
- 30 M€
- Stage
- Series A
- Country
- Finland
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Hadean Ventures , with Tesi , Innovestor Life Science Fund , Finnish Drug Discovery Center , Stephen Industries , Nordic Science Investments , Helsinki University Funds
Provenance
Source sifted
Logged on 24 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.